The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.
 
Shun Lu
Leadership - Innovent BIOLOGICS, INC; Shanghai Fosun; Simcere Zaiming
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio Co. Ltd; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Hansoh (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Lilly Suzhou Pharmaceutical Co. (Inst); Roche (Inst)
 
Jie Wang
No Relationships to Disclose
 
Nong Yang
No Relationships to Disclose
 
Dongqing Lv
No Relationships to Disclose
 
Lijuan Chen
No Relationships to Disclose
 
Lin Wu
No Relationships to Disclose
 
XingYa Li
No Relationships to Disclose
 
Longhua Sun
No Relationships to Disclose
 
Yongfeng Yu
No Relationships to Disclose
 
Bo Jin
No Relationships to Disclose
 
Lin Yang
No Relationships to Disclose
 
Yubiao Guo
No Relationships to Disclose
 
Haipeng Xu
No Relationships to Disclose
 
Tienan Yi
No Relationships to Disclose
 
Aiping Zeng
No Relationships to Disclose
 
Xiaorong Dong
No Relationships to Disclose
 
Jianhua Chen
No Relationships to Disclose
 
Ziping Wang
No Relationships to Disclose
 
Tony Mok
Employment - The Chinese University of Hong Kong
Leadership - AstraZeneca; Aurora Tele-Oncology Platform; HUTCHMED; Insighta Holdings Limited
Stock and Other Ownership Interests - Alentis Therapeutics; AstraZeneca; Aurora Tele-Oncology Platform; Biolidics; D3 Bio; HUTCHMED; Lunit; Prenetics
Honoraria - Abbvie; ACEA Pharmaceutical Research; Adagene; Alpha Biopharma; Amgen; Amoy Diagnostics; AnHeart Therapeutics; AstraZeneca; AVEO; BeiGene; Berry Oncology; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; C4 Therapeutics; CStone Pharmaceuticals; Curio Science; D3; Da Volterra; Daiichi Sankyo/UCB Japan; Daz Group; Eisai; Fishawack Facilitate; Gilead Sciences; GLG’s Healthcare; Gritstone Bio; Guardant Health; Hengrui Therapeutics; Ignyta; Illumina; Incyte; Inivata; InMed; IQVIA; Janssen; Jiahui Holdings Co; Lakeshore Biotechnology; Lilly; Lucence; Lucence; MD Health Brazil,; Medscape; Merck; Merck Sharp & Dohme; MiRXES; Novartis; Novocure; Omega Therapeutics; Origimed; PeerVoice; Permanyer Publications; Pfizer; Physicans' Education Resource; Prenetics; Prime Oncology; Qiming Development (HK) Ltd.; Regeneron; Research to Practice; Roche; Sanofi Aventis GmbH; SFJ Pharmaceutical Ltd; Shanghai BeBirds Translation & Consulting; Shanghai Promedican Pharmaceuticals Co., Ltd; Simcere of America Inc.; Summit Therapeutics Sub, Inc.; Suzhou Liangyihui Network Technology; Synergy Research; Taiho Pharmaceutical; Takeda; Tigermed; touchIME; Vertex; Virtus Medical Group; Xencor; Yuhan
Consulting or Advisory Role - Abbvie; ACEA Pharmaceutical Research; Adagene; Alpha Biopharma; Amgen; Amoy Diagnostics; AstraZeneca; Bayer HealthCare Pharmacuticals; BeiGene; BerGenBio; Berry Oncology; Blueprint Medicines; Boehringer Ingelheim; Bowtie Life Insurance Company; Bridgebio; Bristol-Myers Squibb; C4 Therapeutics; Cirina; Covidien/Medtronic; Covidien/Medtronic; CStone Pharmaceuticals; Curio Science; D3; Da Volterra; Daiichi Sankyo/UCB Japan; Eisai; Elevation Oncology; Fishawack Facilitate; G1 Therapeutics; geneDecode; Genentech; Gilead Sciences; Gritstone Bio; Guardant Health; Hengrui Therapeutics; HUTCHMED; Ignyta; Imagene AI Ltd.; Incyte; Inivata; IQvia; Janssen; Lakeshore Biotechnology; Lilly; Loxo; Lucence; Lunit; Medtronic; Merck Serono; Merck Sharp & Dohme; Mirati Therapeutics; MiRXES; Novartis; Omega Therapeutics; OrigiMed; OSE Immunotherapeutics; Pfizer; Prenetics; PrIME Oncology; Puma Biotechnology; Qiming Development (HK) Ltd.; Regeneron; Roche; SFJ Pharmaceuticals Group; Simcere; Summit Therapeutics; Synergy Research; Takeda; Tigermed; Vertex; Virtus Medical Group; Yuhan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Takeda (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - Abbvie; Astrazeneca; Daiichi Sankyo; Liangyihui; MiRXES; Novartis; Pfizer; Pfizer; Roche; Zai Lab
 
Weiguo Su
Employment - HUTCHMED
Leadership - HUTCHMED
Stock and Other Ownership Interests - HUTCHMED
 
SACHI Study Group
No Relationships to Disclose